Both companies say the collaboration is driven by a shared mission to improve patient outcomes by aligning every step of the diagnostic process
Esprit is a multicenter, randomized, placebo-controlled, double-blind study assessing the safety, pharmacodynamics, and preliminary efficacy of S-606001 as a substrate reduction therapy
The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals
DiaMedica said it plans to launch the trial later in 2026
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
CystoSmart, an AI tool designed to detect bladder tumors during screening and surveillance cystoscopy, is brand-agnostic and works with flexible, rigid, and single-use scopes
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
Hansoh Pharma will receive an upfront payment in the low double-digit millions
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
Subscribe To Our Newsletter & Stay Updated
